^
Association details:
| Biomarker: | MSI-H/dMMR + PD-L1 expression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Trodelvy (sacituzumab govitecan-hziy) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring
Published date:
11/09/2020
Excerpt:
Separate analyses indicated MSI-high and PD-L1 positive tumor status, leading to the initiation of the first line of therapy (nab-paclitaxel and Atezolizumab)….Given non-responsiveness with the first-line therapy, the patient was initiated with sacituzumab govitecan....Continued monitoring of ctDNA demonstrated ctDNA levels <5MTM/mL for a period of two months before serially rising again (to 89.27 MTM/ml). PET-CT ordered in response to increasing ctDNA levels confirmed progression involving hepatic and lung lesions.
DOI:
10.1136/jitc-2020-SITC2020.0025
Test:
